Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kelsi B. Holland"'
Autor:
Meir Wetzler, John Curfman, Michael A. Caligiuri, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Joseph O. Moore, Dean Margeson, Richard A. Larson, Kati Maharry, Susan P. Whitman, Thomas H. Carter, Maria R. Baer, William Blum, Andrew J. Carroll, Yue-Zhong Wu, Jonathan E. Kolitz, Bayard L. Powell, Kelsi B. Holland, Clara D. Bloomfield, Michael D. Radmacher, Krzysztof Mrózek, Guido Marcucci
Publikováno v:
Journal of Clinical Oncology. 29:1373-1381
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloi
Autor:
Kati Maharry, Michael D. Radmacher, Claudia D. Baldus, Kelsi B. Holland, Krzysztof Mrózek, Klaus H. Metzeler, Richard A. Larson, Heiko Becker, Peter Paschka, Andrew J. Carroll, Sebastian Schwind, Dean Margeson, Christopher Hickey, Bayard L. Powell, Susan P. Whitman, Clara D. Bloomfield, Jonathan E. Kolitz, Michael A. Caligiuri, Ramiro Garzon, Guido Marcucci, Shujun Liu
Publikováno v:
Journal of Clinical Oncology. 28:5257-5264
Purpose To evaluate the prognostic significance of expression levels of a single microRNA, miR-181a, in the context of established molecular markers in cytogenetically normal acute myeloid leukemia (CN-AML), and to gain insight into the leukemogenic
Autor:
Michael D. Radmacher, Clara D. Bloomfield, Sebastian Schwind, Dean Margeson, Yue-Zhong Wu, Susan P. Whitman, Richard A. Larson, Jing Wen, Kelsi B. Holland, Meir Wetzler, Michael A. Caligiuri, Heiko Becker, Richard Stone, Klaus H. Metzeler, Joseph O. Moore, Jonathan E. Kolitz, Kati Maharry, Maria R. Baer, Thomas H. Carter, Andrew J. Carroll, Bayard L. Powell, Guido Marcucci, Krzysztof Mrózek
Publikováno v:
Blood. 116:3622-3626
The clinical impact of FLT3-internal tandem duplications (ITDs), an adverse prognostic marker in adults aged < 60 years with primary cytogenetically normal acute myeloid leukemia (CN-AML), requires further investigation in older patients. In CN-AML p
Autor:
Yue-Zhong Wu, Heiko Becker, Jonathan E. Kolitz, Michael A. Caligiuri, Bayard L. Powell, Kati Maharry, Maria R. Baer, Guido Marcucci, Krzysztof Mrózek, Sebastian Schwind, Dean Margeson, Clara D. Bloomfield, Susan P. Whitman, Klaus H. Metzeler, Joseph O. Moore, Kelsi B. Holland, Michael D. Radmacher, Richard A. Larson, Thomas H. Carter, Andrew J. Carroll
Publikováno v:
Blood. 116(25)
BAALC and ERG expression levels are prognostic markers in younger (< 60 years) cytogenetically normal acute myeloid leukemia (CN-AML) adults; their prognostic impact in older (≥ 60 years) patients requires further investigation. We evaluated pretre
Autor:
Michael D. Radmacher, Michael A. Caligiuri, Kati Maharry, Sebastian Schwind, Dean Margeson, Bayard L. Powell, Meir Wetzler, Susan P. Whitman, Guido Marcucci, Kelsi B. Holland, Thomas H. Carter, Andrew J. Carroll, Maria R. Baer, Peter Paschka, Jonathan E. Kolitz, Yue-Zhong Wu, Clara D. Bloomfield, Joseph O. Moore, Heiko Becker, Richard A. Larson, Krzysztof Mrózek
Publikováno v:
Blood. 116(5)
We previously reported the adverse prognostic impact of Wilms tumor 1 gene (WT1) mutations in younger adult cytogenetically normal acute myeloid leukemia (CN-AML). Here, we investigated 243 older (≥ 60 years) primary CN-AML patients. WT1 mutated (W
Autor:
Meir Wetzler, Michael D. Radmacher, Maria R. Baer, Heiko Becker, Klaus H. Metzeler, Clara D. Bloomfield, Kati Maharry, Kelsi B. Holland, Bayard L. Powell, Michael A. Caligiuri, Guido Marcucci, Richard A. Larson, Sebastian Schwind, Dean Margeson, Susan P. Whitman, Jonathan E. Kolitz, Yue-Zhong Wu, Krzysztof Mrózek, Thomas H. Carter, Andrew J. Carroll
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(14)
Purpose To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients and Methods Diagnosti
Autor:
Ravi Vij, Christian Langer, Bayard L. Powell, Michael A. Caligiuri, Michael D. Radmacher, Kelsi B. Holland, Susan P. Whitman, Guido Marcucci, Kati Maharry, Andrew J. Carroll, Claudia D. Baldus, Jonathan E. Kolitz, Krzysztof Mrózek, Clara D. Bloomfield, Richard A. Larson, Peter Paschka
Purpose To determine the prognostic importance of the meningioma 1 (MN1) gene expression levels in the context of other predictive molecular markers, and to derive MN1 associated gene– and microRNA–expression profiles in cytogenetically normal ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d223b4501260ec306c99c527fb016f08
https://europepmc.org/articles/PMC2716941/
https://europepmc.org/articles/PMC2716941/
Autor:
Yue-Zhong Wu, Bayard L. Powell, Sebastian Schwind, John Curfman, Thomas H. Carter, Guido Marcucci, Dean Margeson, Maria R. Baer, Meir Wetzler, Krzysztof Mrózek, Susan P. Whitman, Kati Maharry, Clara D. Bloomfield, Kelsi B. Holland, Andrew J. Carroll, William Blum, Jonathan E. Kolitz, Michael A. Caligiuri, Klaus H. Metzeler, Joseph O. Moore, Heiko Becker, Richard A. Larson, Michael D. Radmacher
Publikováno v:
Blood. 116:98-98
Abstract 98 Mutations in the TET2 gene were recently identified in a variety of myeloid neoplasms including AML. However, the frequency and clinical relevance of TET2 mutations in CN-AML, the largest cytogenetic subgroup of adult AML, have not been w
Autor:
Yue-Zhong Wu, Jonathan E. Kolitz, Maria R. Baer, Heiko Becker, Sebastian Schwind, Dean Margeson, Susan P. Whitman, Kati Maharry, Richard A. Larson, Kelsi B. Holland, Krzysztof Mrózek, Klaus H. Metzeler, Michael A. Caligiuri, Andrew J. Carroll, Clara D. Bloomfield, Michael D. Radmacher, Guido Marcucci
Publikováno v:
Blood. 116:577-577
Abstract 577 Trisomy 8 (+8), the most frequent numerical aberration in AML, occurs in approximately 10% of pts. In one-third of them, +8 is the sole chromosome (chr) anomaly; it is considered to confer an intermediate/adverse prognosis but further st
Autor:
Michael A. Caligiuri, Kati Maharry, Heiko Becker, Yue-Zhong Wu, Sebastian Schwind, Thomas H. Carter, Bayard L. Powell, Kelsi B. Holland, Susan P. Whitman, Radmacher D. Michael, Maria R. Baer, Guido Marcucci, Richard A. Larson, Krzysztof Mrózek, Clara D. Bloomfield
Publikováno v:
Cancer Research. 70:2717-2717
In younger (60 y) requires further evaluation. Pre-therapy bone marrow samples from 140 older de novo CN-AML pts (median age 68 y; range 60 – 81 y) enrolled on cytarabine/daunorubicin-based protocols were studied centrally by RT-PCR. Using the medi